Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
16
PHBBF Quote, Financials, Valuation and Earnings
Last price:
$1.93
Seasonality move
:
0%
Day range:
$1.93 - $1.93
52-week range:
$1.93 - $2.25
Dividend yield:
3.64%
P/E ratio:
--
P/S ratio:
1.44x
P/B ratio:
1.56x
Volume:
--
Avg. volume:
--
1-year change:
-14.22%
Market cap:
$2.5B
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingPharmaron Beijing has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Pharmaron Beijing has an estimated downside of -- from its current price of $1.93.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $1.93.
Fair Value
-
According to the consensus of 0 analysts, Pharmaron Beijing has -- downside to fair value with a price target of -- per share.
PHBBF vs. S&P 500
-
Over the past 5 trading days, Pharmaron Beijing has overperformed the S&P 500 by 2.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pharmaron Beijing does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pharmaron Beijing has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Pharmaron Beijing reported revenues of --.
Earnings Growth
-
Pharmaron Beijing has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Pharmaron Beijing reported earnings per share of --.
Enterprise value:
3B
EV / Invested capital:
--
Price / LTM sales:
1.44x
EV / EBIT:
10.38x
EV / Revenue:
1.86x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
10.38x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2022-03-31 | 2023-03-31 | |
| Income Statement | ||||||
| Revenue | $838.1M | $1.3B | $1.6B | $330.8M | $398M | |
| Gross Profit | $313.2M | $444.8M | $590.2M | $109.4M | $142.4M | |
| Operating Income | $180.6M | $242.9M | $272.6M | $49.4M | $62.8M | |
| EBITDA | $222M | $320.9M | $284.7M | $56M | $69.2M | |
| Diluted EPS | $0.16 | $0.21 | $0.18 | $0.03 | $0.04 | |
| Period Ending | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $266.2M | $729.7M | $769.5M | $1.2B | $953M | |
| Total Assets | $766.2M | $1.3B | $1.9B | $2.9B | $3.1B | |
| Current Liabilities | $190.8M | $140.5M | $349.2M | $485.5M | $571.8M | |
| Total Liabilities | $344.2M | $190.7M | $548.4M | $1.3B | $1.4B | |
| Total Equity | $422M | $1.1B | $1.4B | $1.6B | $1.6B | |
| Total Debt | $230.2M | $25.6M | $184.1M | $783.3M | $789.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2022-03-31 | 2023-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -$615.3M | -$633.9M | -$244.2M | -$66.8M | $17.8M | |
| Cash From Financing | $113M | $476.2M | -$164.2M | -$46.9M | -$94.9K | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
PHBBF
Sector
Market Cap
$2.5B
$43.9M
Price % of 52-Week High
85.78%
45.73%
Dividend Yield
3.64%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-14.22%
-29.11%
Beta (5-Year)
--
0.772
Dividend yield:
3.64%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.93
200-day SMA
Sell
Level
$2.00
Bollinger Bands (100)
Sell
Level
1.93 - 1.93
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$1.93
Relative Strength Index (RSI14)
Sell
Level
0.00
ADX Line
Neutral
Level
Williams %R
Buy
Level
0
50-day SMA
Sell
Level
$1.93
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
0
On Balance Volume
Neutral
Level
1.2K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
Stock Forecast FAQ
In the current month, PHBBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHBBF average analyst price target in the past 3 months is --.
-
Where Will Pharmaron Beijing Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pharmaron Beijing share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Pharmaron Beijing?
Analysts are divided on their view about Pharmaron Beijing share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pharmaron Beijing is a Sell and believe this share price will rise from its current level to --.
-
What Is Pharmaron Beijing's Price Target?
The price target for Pharmaron Beijing over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHBBF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pharmaron Beijing is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PHBBF?
You can purchase shares of Pharmaron Beijing via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pharmaron Beijing shares.
-
What Is The Pharmaron Beijing Share Price Today?
Pharmaron Beijing was last trading at $1.93 per share. This represents the most recent stock quote for Pharmaron Beijing. Yesterday, Pharmaron Beijing closed at $1.93 per share.
-
How To Buy Pharmaron Beijing Stock Online?
In order to purchase Pharmaron Beijing stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
